Completed PHASE4 INTERVENTIONAL 2-arm NCT00169065

Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia (COES)

Clozapine vs. Olanzapine: An Effectiveness Study

Sponsor: Commonwealth Research Center, Massachusetts

Updated 7 times since 2017 Last updated: Apr 6, 2015 Started: Aug 31, 1998 Primary completion: Jun 30, 2002 Completion: Jun 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Schizophrenia and is currently completed. Commonwealth Research Center, Massachusetts leads this study, which shows 7 recorded versions since 1998 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Jan 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Aug 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Commonwealth Research Center, Massachusetts
Dartmouth-Hitchcock Medical Center
Eli Lilly and Company
Harvard Medical School (HMS and HSDM)
National Institute of Mental Health (NIMH)

Data source: Harvard Medical School (HMS and HSDM)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jamaica Plain, United States